ClinicalTrials.gg
RecruitingNCT06650683HirscHADUpdated Nov 10, 2026

Impact of Providing Nursing Support on Parental Stress Related to Preoperative Care of a Newborn With Hirschsprung's Disease

An interventional study of Pediatric HAH in Hirschsprung Disease, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2023, registered Oct 2024).
  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Sex
All
01

Study summary

Impact of providing nursing support on parental stress related to preoperative care of a newborn with Hirschsprung's disease

02

Conditions studied

  • Hirschsprung Disease

Browse trials for

03

In context

Hirschsprung Disease

63 studies on the registry are indexed under Hirschsprung Disease; 24 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 32 interventional studies indexed under Hirschsprung Disease.

Browse Hirschsprung Disease studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Families (one or two parents) with a newborn or infant under 2 months with confirmed or suspected Hirschsprung disease, for whom nursings are effective and performed 1 to 2 times a day while waiting for surgery.
  • With a possible return home before surgery
  • With an information leaflet and non-opposition form signed by one or both parent(s) or by the legal representative.

Exclusion criteria

Exclusion Criteria:

  • The absence of daily nursings
  • Initial ineffectiveness of nursings requiring a digestive stoma
  • Failure to return home before surgery
  • Refusal of one or both parent(s) or legal representative(s)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    With Hospitalisation at Home (HAH)

    families living in Marseille, whose parents will be able to return home under the supervision of nursery nurses from the pediatric HAH.

    Behavioral: Pediatric HAH

  • No intervention
    Without Hospitalisation at Home (HAH)

    Families living outside Marseille whose parents will have to carry out nursings at home independently, without the help of pediatric HAH.

Interventions

  • BehavioralPediatric HAH

    Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.

06

What researchers measure

Primary outcomes

  1. Questionnary to evaluate stress on parents

    Evaluation of the impact on parental stress of nursing support by pediatric HAH in nursery care performed at home by parents as part of their child with Hirschsprung using Perinatal Posttraumatic Stress Disorder Questionnaire (PPQ).

    Time frame: From enrollment to the end of treatment at 6 months

Secondary outcomes

  1. Auto-Questionnary MIB (Mother Infant Bounding) to evaluate the impact of nursing support

    Estimate the impact of nursing support by pediatric HAH in nursery care performed at home by parents on the development of the parent-child bond, the burden felt by parents in relation to their child's illness, the length of pre-operative hospital stay (initial and re-hospitalization), the pre-operative complications (recurrent occlusion, enterocolitis) and the home nursing care provided by parents (quality of nursings, pace of nursings, difficulties encountered, child's tolerance)

    Time frame: From enrollment to the end of treatment at 6 months

  2. Self-Questionnary Burden inventory to evaluate the nursery training provided

    Evaluate nursery training provided by the paramedical team (feedback from parents) : parent training (nursing, understanding illness, understanding illness-related risks) and training aids (sheet, video)

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2023 (actual). Primary completion is estimated for Feb 2027, 41 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Aug 2025 → Feb 2027 and completion Feb 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 21, 2024
StartActual
Aug 14, 2023
Primary completionEst.
Feb 13, 2027was Aug 2025
CompletionEst.
Feb 13, 2027was Feb 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 13, 2025→Feb 13, 2027
Nov 10, 2026
Study completion
Feb 12, 2026→Feb 13, 2027
Nov 10, 2026
Contact
Study contact's phone or email changed: •••1245→•••6682; p•••@ap-hm.fr→m•••@ap-hm.fr. See the current contact
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • APHM · Marseille, FranceContact person changed (no phone or email listed)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Aug 13, 2025→Feb 13, 2027
    Study completion Feb 12, 2026→Feb 13, 2027
    Contact Study contact's phone or email changed: •••1245→•••6682; p•••@ap-hm.fr→m•••@ap-hm.fr. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • APHM · Marseille, FranceContact person changed (no phone or email listed)
    + 4 other changes: identifiers, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06650683
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Aug 14, 2023
Primary completion
Feb 13, 2027 (estimated)
Completion
Feb 13, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Melanie Boulanger
Contact
melanie.boulanger@ap-hm.fr
+33 491386682

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion